The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

August 16, 2019 • By Mary Choy, PharmD, BCGP, FASHP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

It’s important to select the best therapeutic option for & with the patient to improve adherence & for the patient to attain the highest level of satisfaction.

You Might Also Like
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 2: Psoriasis
  • Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss
Explore This Issue
August 2019
Also By This Author
  • Adapting Care During COVID-19: Q&A with Brett Smith, DO

The Drugs

Abatacept (Orencia):8 injection/infusion

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Drug class: selective T cell co-stimulation modulator, DMARD, immunomodulator

Warnings & Precautions

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  • Concomitant use with a tumor necrosis factor inhibitor (TNFi) can increase the risk of (serious) infections. Discontinue abatacept if a serious infection occurs.
  • Anaphylaxis or anaphylactoid reactions can occur after the first infusion and can be life threatening. Appropriate medical support should be immediately available in the event of a reaction. Postmarketing experience reveals at least one case of fatal anaphylaxis following the first abatacept infusion. Following an anaphylactic or other serious allergic reaction, abatacept administration should be stopped immediately with appropriate therapy instituted. Abatacept should be permanently discontinued.
  • Patients with a history of recurrent infections or underlying conditions predisposing them to infections may experience more infections.
  • Screen for latent tuberculosis (TB) prior to initiating therapy. Patients testing positive should be treated prior to abatacept initiation.
  • Live vaccines should not be given concurrently or within three months of abatacept discontinuation.
  • Based on its mechanism of action, abatacept may blunt the effectiveness of some immunizations.
  • Chronic obstructive pulmonary disease patients may develop more frequent respiratory adverse events.

Dosage & Administration

Abatacept is administered by subcutaneous (SQ) injection and intravenous (IV) infusion. The recommended frequency for SQ injection is once weekly, with or without an IV loading dose. For patients initiating therapy with an IV loading dose, administer a single IV infusion (per body weight categories provided in the table below), followed by the first 125 mg SQ injection given within a day of the IV infusion. Patients transitioning from IV therapy to SQ administration should receive the first SQ dose instead of the next scheduled IV dose.

The recommended dose for IV infusion is based on the patient’s body weight.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Commentary

The U.S. Food and Drug Administration (FDA) approved abatacept based on the results of two randomized, controlled trials that involved nearly 3,000 patients. The trials showed that abatacept inhibited joint damage progression independent of patients’ baseline clinical, biochemical or radiographic characteristics. The most common adverse reactions (≥10%) are headache, upper respiratory tract infection, naso­pharyngitis and nausea.

Adalimumab (Humira):9 injection

Biosimilars: adalimumab-atto (Amjevita),10 adalimumab-adbm (Cyltezo),11 adalimumab-
adaz (Hyrimoz)12

Drug class: DMARD, TNFi

Boxed warning: Refer to important safety information (ISI) below, and

  • Fatal hepatosplenic T cell lymphomas (HSTCLs) have occurred post-marketing in adolescent and young adult inflammatory bowel disease (IBD) patients treated with TNFi’s.

*Important Safety Information

This ISI is applicable to all tumor necrosis factor inhibitors (TNFi’s) and some other immune modulators.

Serious Infections & Malignancies

Pages: 1 2 3 4 5 6 7 8 9 10 | Single Page

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: abatacept, adalimumab, anakinra, baricitinib, Certolizumab Pegol, etanercept, Golimumab, infliximab, rituximab, sarilumab, tocilizumab, TofacitinibIssue: August 2019

You Might Also Like:
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 2: Psoriasis
  • Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss
  • Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)